Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of HaemaLogiX, an Australian clinical-stage biotech company that's developing next-generation immunotherapies for multiple myeloma and other plasma cell disorders.

HaemaLogiX is taking a precision approach by targeting novel antigens that are expressed exclusively on malignant plasma cells, sparing healthy ones. Recent peer-reviewed research has validated KMA and LMA as high-value targets, reinforcing the company's unique positioning in the field.

Rosanne shares her journey from antibody engineering to building HaemaLogiX, the science behind their differentiated targets, the latest clinical and preclinical progress, and her perspectives on the future of immunotherapy for blood cancers as the company gears up for key milestones, including a planned IPO later this year.

• 01:15 Meet Rosanne Dunn
• 07:52 HaemalogiX's mission and novel antigens
• 09:53 Overview of multiple myeloma and its symptoms
• 12:19 Targeting malignant plasma cells while sparing normal ones
• 19:25 Recent Peer-Reviewed Research
• 26:08 Synergy with IMiDs like Revlimid
• 29:08 Potential patient impact and quality of life
• 35:05 Planned IPO in 2026 and funding needs

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

• 5 cancers that immunotherapy can cure
• BIO-Europe partnering: Australian biotech companies share their experiences
• How are R&D Tax Incentives shaping Australia’s biotech future?